Clinical trials: Elevated Blood Pressure
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca
Hypertension, Diabetic Nephropathies
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease.
- Trial name
- NCT00168857
- Testing
- telmisartan, losartan
- Where
- 109 sites in United States, Argentina and 8 more
- Volunteers
- 860 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with…
- Trial name
- PAH (NCT01457781)
- Testing
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Where
- 51 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Cardiovascular Diseases, Hyperlipidemias
Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control
- Trial name
- FIMARO (NCT02913794)
- Where
- South Korea
- Volunteers
- 541 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pulmonary Arterial Hypertension
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study…
- Trial name
- NCT02279745
- Testing
- Ralinepag
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 45 people
- Sponsor
- United Therapeutics
Hypertension
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2…
- Trial name
- NCT01983735
- Testing
- TELMINUVO Tab. (80/2.5mg), TELMINUVO Tab. (80/5mg), S-amlodipine 2.5mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
- Trial name
- NCT00160225
- Testing
- Daglutril
- Where
- Italy
- Sponsor
- Solvay Pharmaceuticals
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Hypertension
Renal Denervation in Patients With Refractory Hypertension
To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.
- Trial name
- HTN-1 (NCT00664638)
- Testing
- Symplicty(TM) Catheter System
- Where
- 9 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Medtronic Vascular
Preeclampsia, Hypertension
Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers
Preeclampsia (Pre-E) is a hypertensive disease of pregnancy with multi-system involvement that usually occurs in the second half of pregnancy. Pre-E occurs in 5% to 7% of U.S. pregnancies, and is the third-leading cause of U.S.
- Conditions
- Preeclampsia, Hypertension, Proteinuria, Thrombocytopenia
- Trial name
- NCT02780414
- Where
- 20 sites in United States
- Volunteers
- 1,730 people
- Sponsor
- Progenity, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately…
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
- Trial name
- NCT01896180
- Testing
- ALZ-1101, Latanoprost
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Alleanza Pharmaceuticals, Inc.
Primary Mild and Moderate Hypertension
Study on Human Mass Balance of SPH3127 Tablets
To quantitatively analyze the total radioactivity in the excreta of healthy male subjects after oral administration of [14C] SPH3127, and determine the cumulative excretion rate and main excretion routes of radioactive…
- Trial name
- NCT05593562
- Testing
- SPH3127
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in patients with essential hypertension.
- Trial name
- NCT00446524
- Testing
- Valsartan + Amlodipine besilate
- Where
- Japan
- Volunteers
- 403 people
- Sponsor
- Novartis
Primary Open-angle Glaucoma, Ocular Hypertension
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
- Conditions
- Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT00372827
- Testing
- Brinzolamide 1% added to Travoprost 0.004%
- Where
- Germany
- Volunteers
- 245 people
- Sponsor
- Alcon Research
Brain Injuries, Intracranial Hypertension
Prospective Evaluation of the Non-invasive ICP HeadSense Monitor in TBI Patients Undergoing Invasive ICP Monitoring
Patients with severe traumatic brain injury (TBI) are admitted to the intensive care unit (ICU). Under certain condition (such as a impaired consciousness) the intracranial pressure (ICP) is measured.
- Trial name
- NCT02773862
- Testing
- HS-1000
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- HeadSense Medical
Pulmonary Arterial Hypertension
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01799473
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- United Therapeutics
Essential Hypertension, Type 2 Diabetes Mellitus
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.
- Trial name
- NCT02517866
- Testing
- Azilsartan Medoxomil
- Where
- 11 sites in China, Taiwan and 1 more
- Volunteers
- 380 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.